Pharma Mar, S.A. (FRA:PMRA)
Germany
· Delayed Price · Currency is EUR 72.95
-0.05 (-0.07%)
At close: Dec 3, 2025
Pharma Mar Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 179.28 | 174.86 | 158.15 | 196.34 | 229.83 | 269.96 | Upgrade
|
| Revenue Growth (YoY) | 7.35% | 10.56% | -19.45% | -14.57% | -14.87% | 214.57% | Upgrade
|
| Cost of Revenue | 9.8 | 8.18 | 9.61 | 13.64 | 16.44 | 13.72 | Upgrade
|
| Gross Profit | 169.48 | 166.67 | 148.54 | 182.7 | 213.39 | 256.24 | Upgrade
|
| Selling, General & Admin | 55.31 | 47.18 | 41.81 | 43.24 | 39.74 | 35.77 | Upgrade
|
| Research & Development | 97.12 | 103.5 | 99.3 | 83.45 | 72.17 | 53.79 | Upgrade
|
| Other Operating Expenses | -4.95 | 9.52 | 11.26 | 13.94 | 9.04 | 9.77 | Upgrade
|
| Operating Expenses | 147.48 | 160.2 | 152.37 | 140.63 | 120.95 | 99.6 | Upgrade
|
| Operating Income | 22 | 6.47 | -3.83 | 42.07 | 92.45 | 156.64 | Upgrade
|
| Interest Expense | -4.2 | -2.47 | -2.42 | -2.38 | -3.37 | -3.12 | Upgrade
|
| Interest & Investment Income | 4.82 | 5.68 | 4.32 | 0.88 | 0.37 | 0.34 | Upgrade
|
| Currency Exchange Gain (Loss) | 2.31 | 2.31 | -1.68 | 3.11 | 5.67 | -7.55 | Upgrade
|
| EBT Excluding Unusual Items | 24.92 | 11.99 | -3.61 | 43.68 | 95.12 | 146.31 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | -0.02 | -1.89 | 0.01 | -0.7 | Upgrade
|
| Other Unusual Items | - | - | - | 2 | - | - | Upgrade
|
| Pretax Income | 24.92 | 11.99 | -3.62 | 43.79 | 95.13 | 145.61 | Upgrade
|
| Income Tax Expense | -9.09 | -14.14 | -4.76 | -5.57 | 2.27 | 8.34 | Upgrade
|
| Earnings From Continuing Operations | 34.01 | 26.13 | 1.14 | 49.36 | 92.86 | 137.26 | Upgrade
|
| Net Income to Company | 34.01 | 26.13 | 1.14 | 49.36 | 92.86 | 137.26 | Upgrade
|
| Net Income | 34.01 | 26.13 | 1.14 | 49.36 | 92.86 | 137.26 | Upgrade
|
| Net Income to Common | 34.01 | 26.13 | 1.14 | 49.36 | 92.86 | 137.26 | Upgrade
|
| Net Income Growth | 5367.04% | 2197.71% | -97.70% | -46.85% | -32.35% | - | Upgrade
|
| Shares Outstanding (Basic) | 17 | 18 | 18 | 18 | 18 | 18 | Upgrade
|
| Shares Outstanding (Diluted) | 17 | 18 | 18 | 18 | 18 | 18 | Upgrade
|
| Shares Change (YoY) | - | -1.98% | -0.81% | -0.12% | -1.31% | -0.77% | Upgrade
|
| EPS (Basic) | 1.95 | 1.49 | 0.06 | 2.73 | 5.14 | 7.50 | Upgrade
|
| EPS (Diluted) | 1.95 | 1.49 | 0.06 | 2.73 | 5.13 | 7.49 | Upgrade
|
| EPS Growth | - | 2382.56% | -97.80% | -46.78% | -31.51% | - | Upgrade
|
| Free Cash Flow | 16.72 | -8.99 | -28.25 | 29.47 | 17.87 | 275.94 | Upgrade
|
| Free Cash Flow Per Share | 0.96 | -0.51 | -1.58 | 1.63 | 0.99 | 15.06 | Upgrade
|
| Dividend Per Share | - | 0.800 | 0.650 | 0.650 | 0.650 | 0.600 | Upgrade
|
| Dividend Growth | - | 23.08% | - | - | 8.33% | 25.00% | Upgrade
|
| Gross Margin | 94.53% | 95.32% | 93.92% | 93.05% | 92.85% | 94.92% | Upgrade
|
| Operating Margin | 12.27% | 3.70% | -2.42% | 21.43% | 40.22% | 58.03% | Upgrade
|
| Profit Margin | 18.97% | 14.94% | 0.72% | 25.14% | 40.40% | 50.84% | Upgrade
|
| Free Cash Flow Margin | 9.33% | -5.14% | -17.87% | 15.01% | 7.78% | 102.21% | Upgrade
|
| EBITDA | 26.95 | 10.07 | -1.15 | 44.88 | 94.99 | 159.09 | Upgrade
|
| EBITDA Margin | 15.03% | 5.76% | -0.73% | 22.86% | 41.33% | 58.93% | Upgrade
|
| D&A For EBITDA | 4.95 | 3.6 | 2.68 | 2.81 | 2.54 | 2.45 | Upgrade
|
| EBIT | 22 | 6.47 | -3.83 | 42.07 | 92.45 | 156.64 | Upgrade
|
| EBIT Margin | 12.27% | 3.70% | -2.42% | 21.43% | 40.22% | 58.03% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 2.39% | 5.73% | Upgrade
|
| Revenue as Reported | 179.28 | 174.86 | 158.15 | 196.34 | 229.83 | 269.96 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.